Noerr advises Telekom on the acquisition of frequencies in the 3.5 GHz spectrum
A team of Noerr lawyers has advised Telekom Deutschland GmbH on the acquisition of several frequencies in the 3.5 GHz spectrum. The…
Noerr advises Deutsche Telekom on the takeover of mobile network sites from Telefónica Deutschland
Noerr has advised Deutsche Telekom AG on the takeover of 7,000 mobile network sites from Telefónica Deutschland. The…
Clifford Chance advises METRO GROUP on the sale of the majority shareholding in 10 Real hypermarket sites to Carlton Investment
Clifford Chance advised METRO PROPERTIES, the real estate subsidiary of METRO GROUP, on the divestment of the majority shareholding in…
King & Wood Mallesons advises Greenland on its Back-door Listing
King & Wood Mallesons (“KWM”) advised Greenland Holding Group (“Greenland”) on its successful completion of…
Hengeler Mueller advises Lupin on acquisition of product portfolio from Temmler
Lupin Limited (“Lupin”), a leading Indian pharmaceutical company, announced on 24 July 2015 that it has entered into a…
Advising Longsol BV in connection with the sale of two solar power plant to DIF Infrastructures III
Advising Longsol BV in connection with the sale to DIF Infrastructure III of 100% of the shares of the 8.9 MW Valence sur Baïse and…
Delphi advisor to Obligo Investment Management AS (“Obligo”) in the divestment of real estate portfolios
Delphi has been legal advisor to Obligo Investment Management AS (“Obligo”) in the divestment of real estate portfolios with…
White & Case Advises LFPI on Acquisition of Alliance Hotel Group From Lone Star
White & Case LLP has advised LFPI, one of the premier independent multi-strategy alternative asset managers in Europe, on its…
DWF advises Bladnoch Distillery Limited on landmark acquisition
DWF has advised Bladnoch Distillery Limited on its acquisition of Bladnoch Distillery in South West Scotland, which marks the return of…
Wragge Lawrence Graham & Co's Life Sciences team has advised AstraZeneca on its agreement with Genzyme to divest rare disease medicine Caprelsa
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease…